Rheumatology 1999; 38: 992-996
© 1999 British Society for Rheumatology
Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy
Division of Internal Medicine, Department of Internal Medicine,
1 Division of Rheumatology, Department of Internal Medicine,
2 Institute of Radiology, University of Genoa,
3 2° Division of Pneumology, San Martino Hospital, Genoa, and
4 Division of Gastroenterology, Department of Internal Medicine, University of Genoa, Italy
Correspondence to:
F. Indiveri, Dipartimento di Medicina Interna, Universitá di Genova, viale Benedetto XV n.6, 16132 Genova, Italy.
Objectives. The main aim was to analyse the long-term therapeutic effects on systemic sclerosis (SSc) patients of treatment with either (i) iloprost alone or (ii) low-dose oral cyclosporin A (CyA) associated with iloprost. A secondary aim was to analyse interleukin-6 (IL-6) serum levels in SSc patients before and after 1 yr of treatment.
Methods. A clinical trial was performed in which 20 consecutive SSc patients were alternately randomized into two homogeneous groups receiving either monthly i.v. iloprost (1 ng/kg/min in 6 h i.v. infusion, for 5 consecutive days, 1 week per month) (Group I) or low-dose CyA (2.5 mg/kg/day) associated with iloprost administration (Group II). IL-6 concentrations were evaluated by ELISA in the sera of each patient before and after 1 yr of therapy and in 20 healthy subjects.
Results. After 1 yr of therapy, a significant improvement of skin (P=0.008), microvascular (P=0.004) and oesophageal (P=0.05) morphological and functional parameters was observed only in Group II patients. Furthermore, after 1 yr of treatment, a significant reduction (P=0.007) of IL-6 serum concentration was observed only in Group II patients.
Conclusions. Collectively, our data suggest that the combination of low-dose CyA with iloprost administration may be of clinical utility in SSc and that a mechanism of action of CyA in SSc may include the decrease in IL-6 production.
KEY WORDS: Systemic sclerosis, Cyclosporin A, Iloprost, Interleukin 6.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. SULLI, S. SOLDANO, C. PIZZORNI, P. MONTAGNA, M. E. SECCHI, B. VILLAGGIO, B. SERIOLO, R. BRIZZOLARA, and M. CUTOLO Raynaud's Phenomenon and Plasma Endothelin: Correlations with Capillaroscopic Patterns in Systemic Sclerosis J Rheumatol, June 1, 2009; 36(6): 1235 - 1239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Mugii, M. Hasegawa, Y. Hamaguchi, C. Tanaka, K. Kaji, K. Komura, I. Ueda-Hayakawa, S. Horie, M. Ikuta, K. Tachino, et al. Reduced red blood cell velocity in nail-fold capillaries as a sensitive and specific indicator of microcirculation injury in systemic sclerosis Rheumatology, June 1, 2009; 48(6): 696 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Aschwanden, T Daikeler, K A Jaeger, C Thalhammer, A Gratwohl, M Matucci-Cerinic, and A Tyndall Rapid improvement of nailfold capillaroscopy after intense immunosuppression for systemic sclerosis and mixed connective tissue disease Ann Rheum Dis, July 1, 2008; 67(7): 1057 - 1059. [Full Text] [PDF]
|
|
|
|
|
|
G. Filaci, M. Cutolo, M. Basso, G. Murdaca, L. Derchi, R. Gianrossi, F. Ropolo, P. Zentilin, A. Sulli, F. Puppo, et al. Long-term treatment of patients affected by systemic sclerosis with cyclosporin A Rheumatology, December 1, 2001; 40(12): 1431 - 1432. [Full Text] [PDF]
|
|